Platelet function testing: state of the art

References

• Rodeghiero F, Castaman G, Dini E. Epidemiological investigation of the prevalence of von Willebrand’s disease. Blood69(2), 454–459 (1987).
   PubMed Web of Science ®Google Scholar
• Harrison P. Progress in the assessment of platelet function. Br. J. Haematol.111(3), 733–744 (2000).
   PubMed Web of Science ®Google Scholar
• Philipp CS, Dilley A, Miller CH et al. Platelet functional defects in women with unexplained menorrhagia. J. Thromb. Haemost.1(3), 477–484 (2003).
   PubMed Web of Science ®Google Scholar
• Quiroga T, Goycoolea M, Munoz B et al. Template bleeding time and PFA-100 have low sensitivity to screen patients with hereditary mucocutaneous hemorrhages: comparative study in 148 patients. J. Thromb. Haemost.2(6), 892–898 (2004).
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Lecchi A, Agati B, Lombardi R, Zighetti ML. Evaluation of platelet function with the PFA-100 system in patients with congenital defects of platelet secretion. Thromb. Res.96(3), 213–217 (1999).
   PubMed Web of Science ®Google Scholar
• Kerenyi A, Schlammadinger A, Ajzner E et al. Comparison of PFA-100 closure time and template bleeding time of patients with inherited disorders causing defective platelet function. Thromb. Res.96(6), 487–492 (1999).
   PubMed Web of Science ®Google Scholar
• Peterson P, Hayes TE, Arkin CF et al. The preoperative bleeding time test lacks clinical benefit: College of American Pathologists’ and American Society of Clinical Pathologists’ position article. Arch. Surg.133(2), 134–139 (1998).
   PubMedGoogle Scholar
• Duke WW. The relation of blood platelets to hemorrhagic disease. JAMA55, 1185–1192 (198).
   Google Scholar
• Wandt H, Frank M, Ehninger G et al. The bleeding time as a screening test for evaluation of platelet function. N. Engl. J. Med.287(4), 155–159 (1972).
   PubMed Web of Science ®Google Scholar
• Harker LA, Slichter SJ. Safety and cost effectiveness of a 10 × 109/l trigger for prophylactic platelet transfusions compared with the traditional 20 × 109/l trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia. Blood91(10), 3601–3606 (1998).
   PubMed Web of Science ®Google Scholar
• Gewirtz AS, Miller ML, Keys TF. The clinical usefulness of the preoperative bleeding time. Arch. Pathol. Lab. Med.120(4), 353–356 (1996).
   PubMed Web of Science ®Google Scholar
• Lind SE. The bleeding time does not predict surgical bleeding. Blood77(12), 2547–2552 (1991).
   PubMed Web of Science ®Google Scholar
• Rodeghiero F, Castaman G, Tosetto A et al. The discriminant power of bleeding history for the diagnosis of type 1 von Willebrand disease: an international, multicenter study. J. Thromb. Haemost.3(12), 2619–2626 (2005).
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Are the bleeding time and PFA-100 useful in the initial screening of patients with mucocutaneous bleedings of hereditary nature?J. Thromb. Haemost.2(6), 890–891 (2004).
   PubMed Web of Science ®Google Scholar
• Francis J, Francis D, Larson L, Helms E, Garcia M. Can the Platelet Function Analyzer (PFA)-100 test substitute for the template bleeding time in routine clinical practice? Platelets10(2), 132–136 (1999).
   PubMed Web of Science ®Google Scholar
• Kratzer MA, Born GV. Simulation of primary haemostasis in vitro. Haemostasis15(6), 357–362 (1985).
   PubMedGoogle Scholar
• Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer – PFA-100. Semin. Thromb. Hemost.21(Suppl. 2), 106–112 (1995).
   PubMedGoogle Scholar
• Harrison P. The role of PFA-100 testing in the investigation and management of haemostatic defects in children and adults. Br. J. Haematol.130(1), 3–10 (2005).
   PubMed Web of Science ®Google Scholar
• Carcao MD, Blanchette VS, Dean JA et al. The Platelet Function Analyzer (PFA-100): a novel in-vitro system for evaluation of primary haemostasis in children. Br. J. Haematol.101(1), 70–73 (1998).
   PubMed Web of Science ®Google Scholar
• Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation iwth the PFA-100 platelet function analyser. Platelets11(6), 320–324 (2000).
   PubMed Web of Science ®Google Scholar
• Bock M, De Haan J, Beck KH et al. Standardization of the PFA-100 (R) platelet function test in 105 mmol/l buffered citrate: effect of gender, smoking, and oral contraceptives. Br. J. Haematol.106(4), 898–904 (1999).
   PubMed Web of Science ®Google Scholar
• Harrison P, Robinson MS, Mackie IJ et al. Performance of the platelet function analyser PFA-100 in testing abnormalities of primary Haemostasis Blood Coagul. Fibrinolysis10(1), 25–31 (1999).
   PubMed Web of Science ®Google Scholar
• Moeller A, Weippert-Kretschmer M, Prinz H, Kretschmer V. Influence of ABO blood groups on primary hemostasis. Transfusion41(1), 56–60 (2001).
   PubMed Web of Science ®Google Scholar
• Pamukcu B, Oflaz H, Onur I et al. Clinical relevance of aspirin resistance in patients with stable coronary artery disease: a prospective follow-up study (PROSPECTAR). Blood Coagul. Fibrinolysis18(2), 187–192 (2007).
   PubMed Web of Science ®Google Scholar
• Jilma B. Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction. J. Lab. Clin. Med.138(3), 152–163 (2001).
   PubMed Web of Science ®Google Scholar
• Ziegler S, Alt E, Brunner M, Speiser W, Minar E. Influence of systemic inflammation on the interpretation of response to antiplatelet therapy, monitored by PFA-100. Semin. Thromb. Hemost.31(4), 416–419 (2005).
   PubMed Web of Science ®Google Scholar
• Mammen EF, Comp PC, Gosselin R et al. PFA-100 system: a new method for assessment of platelet dysfunction. Semin. Thromb. Hemost.24(2), 195–202 (1998).
   PubMed Web of Science ®Google Scholar
• Hayward CP, Harrison P, Cattaneo M, Ortel TL, Rao AK. The Platelet Physiology Subcommittee of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis Platelet function analyzer (PFA)-100 closure time in the evaluation of platelet disorders and platelet function. J. Thromb. Haemost.4(2), 312–319 (2006).
   PubMed Web of Science ®Google Scholar
• Franchini M. The platelet function analyzer (PFA-100): an update on its clinical use. Clin. Lab.51(7–8), 367–372 (2005).
   PubMed Web of Science ®Google Scholar
• Wuillemin WA, Gasser KM, Zeerleder SS, Lammle B. Evaluation of a Platelet Function Analyser (PFA-100) in patients with a bleeding tendency. Swiss Med. Wkly132(31–32), 443–448 (2002).
   PubMed Web of Science ®Google Scholar
• Posan E, McBane RD, Grill DE, Motsko CL, Nichols WL. Comparison of PFA-100 testing and bleeding time for detecting platelet hypofunction and von Willebrand disease in clinical practice. Thromb. Haemost.90(3), 483–490 (2003).
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. The utility of the PFA-100 in the identification of von Willebrand disease: a concise review. Semin. Thromb. Hemost.32(5), 537–545 (2006).
   PubMed Web of Science ®Google Scholar
• Favaloro EJ. Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations. Haemophilia7(2), 170–179 (2001).
   PubMed Web of Science ®Google Scholar
• Franchini M, Gandini G, Manzato F, Lippi G. Evaluation of the PFA-100 system for monitoring desmopressin therapy in patients with type 1 von Willebrand’s disease. Haematologica87(6), 670 (2002).
   PubMed Web of Science ®Google Scholar
• Fressinaud E, Veyradier A, Sigaud M, Boyer-Neumann C, Le Boterff C, Meyer D. Therapeutic monitoring of von Willebrand disease: interest and limits of a platelet function analyser at high shear rates. Br. J. Haematol.106(3), 777–783 (1999).
   PubMed Web of Science ®Google Scholar
• Poulsen TS, Mickley H, Korsholm L, Licht PB, Haghfelt T, Jorgensen B. Using the Platelet Function Analyzer-100 for monitoring aspirin therapy. 120(2),161-72 Thromb. Res. (2007).
   PubMed Web of Science ®Google Scholar
• Alstrom U, Tyden H, Oldgren J, Siegbahn A, Stahle E. The platelet inhibiting effect of a clopidogrel bolus dose in patients on long-term acetylsalicylic acid treatment. 120(3), 353-9 Thromb. Res. (2007).
   PubMed Web of Science ®Google Scholar
• Hezard N, Metz D, Nazeyrollas P et al. Use of the PFA-100 apparatus to assess platelet function in patients undergoing PTCA during and after infusion of c7E3 Fab in the presence of other antiplatelet agents. Thromb. Haemost.83(4), 540–544 (2000).
   PubMed Web of Science ®Google Scholar
• Koscielny J, von Tempelhoff GF, Ziemer S et al. A practical concept for preoperative management of patients with impaired primary hemostasis. Clin. Appl. Thromb. Hemost.10(2), 155–166 (2004).
   PubMed Web of Science ®Google Scholar
• Koscielny J, Ziemer S, Radtke H et al. A practical concept for preoperative identification of patients with impaired primary hemostasis. Clin. Appl. Thromb. Hemost.10(3), 195–204 (2004).
   PubMed Web of Science ®Google Scholar
• Rodgers RP, Levin J. A critical reappraisal of the bleeding time. Semin. Thromb. Hemost.16(1), 1–20 (1990).
   PubMed Web of Science ®Google Scholar
• Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature194, 927–929 (1962).
   PubMed Web of Science ®Google Scholar
• Dyszkiewicz-Korpanty AM, Frenkel EP, Sarode R. Approach to the assessment of platelet function: comparison between optical-based platelet-rich plasma and impedance-based whole blood platelet aggregation methods. Clin. Appl. Thromb. Hemost.11(1), 25–35 (2005).
   PubMed Web of Science ®Google Scholar
• Zhou L, Schmaier AH. Platelet aggregation testing in platelet-rich plasma: description of procedures with the aim to develop standards in the field. Am. J. Clin. Pathol.123(2), 172–183 (2005).
   PubMed Web of Science ®Google Scholar
• Sweeney JD, Labuzetta JW, Fitzpatrick JE. The effect of the platelet count on the aggregation response and adenosine triphosphate release in an impedance lumi-aggregometer. Am. J. Clin. Pathol.89(5), 655–659 (1988).
   PubMed Web of Science ®Google Scholar
• Israels SJ, McNicol A, Robertson C, Gerrard JM. Platelet storage pool deficiency: diagnosis in patients with prolonged bleeding times and normal platelet aggregation. Br. J. Haematol.75(1), 118–121 (1990).
   PubMed Web of Science ®Google Scholar
• Nieuwenhuis HK, Akkerman JW, Sixma JJ. Patients with a prolonged bleeding time and normal aggregation tests may have storage pool deficiency: studies on one hundred six patients. Blood70(3), 620–623 (1987).
   PubMed Web of Science ®Google Scholar
• Feinman RD, Lubowsky J, Charo I, Zabinski MP. The lumi-aggregometer: a new instrument for simultaneous measurement of secretion and aggregation by platelets. J. Lab. Clin. Med.90(1), 125–129 (1977).
   PubMed Web of Science ®Google Scholar
• White MM, Foust JT, Mauer AM, Robertson JT, Jennings LK. Assessment of lumiaggregometry for research and clinical laboratories. Thromb. Haemost.67(5), 572–577 (1992).
   PubMed Web of Science ®Google Scholar
• Cardinal DC, Flower RJ. The electronic aggregometer: a novel device for assessing platelet behavior in blood. J. Pharmacol. Methods3(2), 135–158 (1980).
   PubMedGoogle Scholar
• Ingerman-Wojenski CM, Silver MJ. A quick method for screening platelet dysfunctions using the whole blood lumi-aggregometer. Thromb. Haemost.51(2), 154–156 (1984).
   PubMed Web of Science ®Google Scholar
• Riess H, Braun G, Brehm G, Hiller E. Critical evaluation of platelet aggregation in whole human blood. Am. J. Clin. Pathol.85(1), 50–56 (1986).
   PubMed Web of Science ®Google Scholar
• Sweeney JD, Hoernig LA, Fitzpatrick JE. Whole blood aggregation in von Willebrand disease. Am. J. Hematol.32(3), 190–193 (1989).
   PubMed Web of Science ®Google Scholar
• Santos MT, Valles J, Marcus AJ et al. Enhancement of platelet reactivity and modulation of eicosanoid production by intact erythrocytes. A new approach to platelet activation and recruitment. J. Clin. Invest.87(2), 571–580 (1991).
   PubMed Web of Science ®Google Scholar
• Matsagas M, Jagroop IA, Geroulakos G, Mikhailidis DP. The effect of a loading dose (300 mg) of clopidogrel on platelet function in patients with peripheral arterial disease. Clin. Appl. Thromb. Hemost.9(2), 115–120 (2003).
   PubMed Web of Science ®Google Scholar
• Moffat KA, Ledford-Kraemer MR, Nichols WL, Hayward CP. North American Specialized Coagulation Laboratory Association. Variability in clinical laboratory practice in testing for disorders of platelet function: results of two surveys of the North American Specialized Coagulation Laboratory Association. Thromb. Haemost.93(3), 549–553 (2005).
   PubMed Web of Science ®Google Scholar
• Sweeney JD, Hoernig LA, Michnik A, Fitzpatrick JE. Whole blood aggregometry. Influence of sample collection and delay in study performance on test results. Am. J. Clin. Pathol.92(5), 676–679 (1989).
   PubMed Web of Science ®Google Scholar
• Quiroga T, Perez M, Rodriguez S et al. Skin and mucous membrane hemorrhages: clinical assessment, study sequence and relative frequency of hereditary diseases of the hemostasis in a Chilean population. Rev. Med. Chil.125(4), 409–418 (1997).
   PubMed Web of Science ®Google Scholar
• Schmitz G, Rothe G, Ruf A et al. European Working Group on Clinical Cell Analysis: consensus protocol for the flow cytometric characterisation of platelet function. Thromb. Haemost.79(5), 885–896 (1998).
   PubMed Web of Science ®Google Scholar
• Michelson AD. Flow cytometry: a clinical test of platelet function. Blood87(12), 4925–4936 (1996).
   PubMed Web of Science ®Google Scholar
• Hickerson DH, Bode AP. Flow cytometry of platelets for clinical analysis. Hematol. Oncol. Clin. North Am.16(2), 421–454 (2002).
   PubMed Web of Science ®Google Scholar
• Wall JE, Buijs-Wilts M, Arnold JT et al. A flow cytometric assay using mepacrine for study of uptake and release of platelet dense granule contents. Br. J. Haematol.89(2), 380–385 (1995).
   PubMed Web of Science ®Google Scholar
• Gobbi G, Mirandola P, Tazzari PL et al. Flow cytometry detection of serotonin content and release in resting and activated platelets. Br. J. Haematol.121(6), 892–896 (2003).
   PubMed Web of Science ®Google Scholar
• Gordon N, Thom J, Cole C, Baker R. Rapid detection of hereditary and acquired platelet storage pool deficiency by flow cytometry. Br. J. Haematol.89(1), 117–123 (1995).
   PubMed Web of Science ®Google Scholar
• Jennings LK, Ashmun RA, Wang WC, Dockter ME. Analysis of human platelet glycoproteins IIb-IIIa and Glanzmann’s thrombasthenia in whole blood by flow cytometry. Blood68(1), 173–179 (1986).
   PubMed Web of Science ®Google Scholar
• Shattil SJ, Cunningham M, Hoxie JA. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry. Blood70(1), 307–315 (1987).
   PubMed Web of Science ®Google Scholar
• Dachary-Prigent J, Freyssinet JM, Pasquet JM, Carron JC, Nurden AT. Annexin V as a probe of aminophospholipid exposure and platelet membrane vesiculation: a flow cytometry study showing a role for free sulfhydryl groups. Blood81(10), 2554–2565 (1993).
   PubMed Web of Science ®Google Scholar
• Warkentin TE, Hayward CP, Boshkov LK et al. Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: an explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood84(11), 3691–3699 (1994).
   PubMed Web of Science ®Google Scholar
• Abrams C, Shattil SJ. Immunological detection of activated platelets in clinical disorders. Thromb. Haemost.65(5), 467–473 (1991).
   PubMed Web of Science ®Google Scholar
• Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur. Heart J.27(6), 647–654 (2006).
   PubMed Web of Science ®Google Scholar
• Patrono C. Aspirin resistance: definition, mechanisms and clinical read-outs. J. Thromb. Haemost.1(8), 1710–1713 (2003).
   PubMed Web of Science ®Google Scholar
• Altman R, Luciardi HL, Muntaner J, Herrera RN. The antithrombotic profile of aspirin. Aspirin resistance, or simply failure? Thromb. J.2(1), 1 (2004).
   PubMedGoogle Scholar
• Cattaneo M. Aspirin and clopidogrel: efficacy, safety, and the issue of drug resistance. Arterioscler. Thromb. Vasc. Biol.24(11), 1980–1987 (2004).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet367(9510), 606–617 (2006).
   PubMed Web of Science ®Google Scholar
• Hankey GJ, Eikelboom JW. Aspirin resistance. Br. Med. J.328(7438), 477–479 (2004).
   PubMed Web of Science ®Google Scholar
• Michelson AD, Cattaneo M, Eikelboom JW et al. Aspirin resistance: position paper of the Working Group on Aspirin Resistance. J. Thromb. Haemost.3(6), 1309–1311 (2005).
   PubMed Web of Science ®Google Scholar
• Nguyen TA, Diodati JG, Pharand C. Resistance to clopidogrel: a review of the evidence. J. Am. Coll. Cardiol.45(8), 1157–1164 (2005).
   PubMed Web of Science ®Google Scholar
• Dalen JE. Aspirin resistance: is it real? Is it clinically significant? Am. J Med.120, 1–4 (2007).
   PubMed Web of Science ®Google Scholar
• Schwartz KA, Schwartz DE, Ghosheh K, Reeves MJ, Barber K, DeFranco A. Compliance as a critical consideration in patients who appear to be resistant to aspirin after healing of myocardial infarction. Am. J. Cardiol.95(8), 973–975 (2005).
   PubMed Web of Science ®Google Scholar
• Buchanan MR, Brister SJ. Individual variation in the effects of aspirin on platelet function: implications for the use of aspirin clinically. Can. J. Cardiol.11(3), 221–227 (1995).
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Samara W et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J. Am. Coll. Cardiol.46(10), 1827–1832 (2005).
   PubMed Web of Science ®Google Scholar
• Matetzky S, Shenkman B, Guetta V et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation109(25), 3171–3175 (2004).
   PubMed Web of Science ®Google Scholar
• Michelson AD, Linden MD, Furman MI et al. Evidence that pre-existent variability in platelet response to ADP accounts for ‘clopidogrel resistance’. J. Thromb. Haemost.5(1), 75–81 (2007).
   PubMed Web of Science ®Google Scholar
• Fressinaud E, Veyradier A, Truchaud F et al. Screening for von Willebrand disease with a new analyzer using high shear stress: a study of 60 cases. Blood91(4), 1325–1331 (1998).
   PubMed Web of Science ®Google Scholar
• Cattaneo M, Federici AB, Lecchi A et al. Evaluation of the PFA-100 system in the diagnosis and therapeutic monitoring of patients with von Willebrand disease. Thromb. Haemost.82(1), 35–39 (1999).
   PubMed Web of Science ®Google Scholar
• Kottke-Marchant K, Corcoran G. The laboratory diagnosis of platelet disorders. Arch. Pathol. Lab. Med.126(2), 133–146 (2002).
   PubMed Web of Science ®Google Scholar
• Feinman RD, Detwiler TC, Ingerman-Wojenski C. The lumi-aggregometer as a research and clinical tool. In: The Platelets: Physiology and Pharmacology. Academic Press, CA, USA 429–439 (1985).
   Google Scholar